Just published a piece on BioPharmaTrend: “AI Is Key to Democratizing Drug Discovery.” I share why Bioptic is building Google-scale tools to help biotech startups compete—and win. AI is no longer a luxury. It’s the new power grid.
I just published a piece on BioPharmaTrend.com titled “AI Is Key to Democratizing Drug Discovery.” It’s personal.
Drug discovery is broken. Big Pharma is scaling back early R&D, leaning on in-licensing instead. That leaves over 20,000 biotech startups in the arena, fighting for capital, talent, and time—without the infrastructure to compete.
But AI changes the game.
In the piece, I draw a parallel from my days at Google, where we launched the YouTube app and made global video creation a tap away. That same model—powerful platform, simple interface, zero-to-scale infrastructure—is what we’re building at Bioptic.
Today, you shouldn’t need a billion-dollar lab to design a molecule. You need a good idea, and a great AI partner.
That’s where Bioptic comes in. We’ve built an AI-native drug discovery platform—by ex-Googlers, pharma pros, and computational scientists—that lets any team, big or small, go from target to lead faster than ever. Think of it like AWS for drug hunters. You bring the biology. We bring the horsepower.
This isn’t just vision—it’s happening. From launching PLUMBER on Polaris to presenting our BELKA-winning AI at NeurIPS, we’re proving that generative AI can give biotech its next big leap.
If you’re building in this space, I’d love your take.
Let’s build the future. One molecule at a time.
—Andrey